Skip to main content

Table 2 Absorbed doses in the tumour and normal organs in mice with subcutaneous PANC-1 xenografts treated with RICs

From: Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu

  Absorbed Dose (Mean ± SD; Gy) a
Organ Panitumumab-DOTA-[111In]In b Panitumumab-MCP-[111In]In b Panitumumab-DOTA-[177Lu]Lu c
Heart 1.9 ± 0.4 2.2 ± 0.1 2.5 ± 0.3
Lungs 2.5 ± 0.7 2.3 ± 0.3 4.0 ± 1.3
Liver 2.8 ± 0.6 6.1 ± 0.6 6.5 ± 0.9
Spleen 4.5 ± 1.4 7.5 ± 0.7 6.3 ± 1.1
Pancreas 1.4 ± 0.2 2.0 ± 0.3 5.3 ± 1.9
Stomach 1.2 ± 0.2 1.8 ± 0.1 0.9 ± 0.1
Intestine 1.5 ± 0.3 1.4 ± 0.2 0.6 ± 0.1
Kidneys 5.3 ± 0.7 5.2 ± 0.3 7.8 ± 1.1
Whole Body 1.7 ± 0.2 1.5 ± 0.1 1.3 ± 0.1
Tumour 8.8 ± 3.0 2.6 ± 0.3 11.6 ± 4.9
  1. aEstimated using \( D=\sum {\overset{\sim }{A}}_S\times {S}_{T\leftarrow S} \), where \( {\overset{\sim }{A}}_S \) is the time-integrated activity (Bq × sec) in the source organ (see Supplementary Fig. S2), and S is the Snyder factor for mouse organs (Bitar et al., 2007). The tumour dose was estimated using the sphere model in OLINDA/EXM dosimetry software and the tumour size (Stabin et al., 2005)
  2. bAbsorbed dose for NOD/SCID mice injected i.v. (tail vein) with three amounts (10 MBq; 10 μg; ~ 0.07 nmoles) of 111In-labeled RICs separated by 3 weeks
  3. cAbsorbed dose for NRG mice injected i.v. (tail vein) with a single amount (6 MBq; 10 μg; ~ 0.07 nmoles) of 177Lu-labeled RICs